Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432
Authors:
Eric Jacobsen
Pier Luigi Zinzani
Jasmine Zain
Monica Mead
Carla Casulo
Giuseppe Gritti
Lauren Pinter‐Brown
Koji Izutsu
Marci Daugherty
Jonathan E. Brammer
Neha Mehta-Shah
Barbara Pro
Steven M. Horwitz
Affiliated Authors:
Barbara Pro
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2022-169432
DOI:
10.1182/blood-2022-169432
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: